Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 16/20 | 0.39 |
| ▸ | JAK2 | O60674 | 15/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41148 | 0.81 | JAK2 (0.41) | SRCJAK1JAK2TTK | |
| SCHEMBL41177 | 0.79 | LRRK2 (0.46) | SRCABL1PDGFRBJAK1JAK2 | |
| SCHEMBL611762 | 0.75 | SRC (0.53) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL41482 | 0.74 | LRRK2 (0.46) | SRCPDGFRBJAK2TTK | |
| SCHEMBL614249 | 0.74 | JAK3 (0.46) | SRCABL1JAK1JAK2TTK | |
| SCHEMBL614439 | 0.73 | TTK (0.42) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL41292 | 0.73 | LRRK2 (0.49) | SRCABL1PDGFRBJAK2TTK | |
| SCHEMBL41122 | 0.73 | SRC (0.53) | SRCPDGFRBJAK2TTK | |
| SCHEMBL41008 | 0.73 | LRRK2 (0.44) | SRCABL1YES1PDGFRBKDR | |
| SCHEMBL613379 | 0.73 | LRRK2 (0.47) | SRCABL1YES1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2013-05-16 | — | — | US | claimed |
| EP-2585439-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Fovea Pharmaceuticals (FR) | 2013-05-01 | — | — | EP | claimed |
| WO-2011161159-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | FOVEA PHARMACEUTICALS (FR) | 2011-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123271-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION | CAMK2D, CAMK2A, CAMK2B | SRC 401/4885ABL1 181/4885YES1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.